1. Home
  2. PHAT vs HRTX Comparison

PHAT vs HRTX Comparison

Compare PHAT & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • HRTX
  • Stock Information
  • Founded
  • PHAT 2018
  • HRTX 1983
  • Country
  • PHAT United States
  • HRTX United States
  • Employees
  • PHAT N/A
  • HRTX N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • HRTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHAT Health Care
  • HRTX Health Care
  • Exchange
  • PHAT Nasdaq
  • HRTX Nasdaq
  • Market Cap
  • PHAT 289.0M
  • HRTX 325.0M
  • IPO Year
  • PHAT 2019
  • HRTX 1987
  • Fundamental
  • Price
  • PHAT $4.25
  • HRTX $1.88
  • Analyst Decision
  • PHAT Strong Buy
  • HRTX Strong Buy
  • Analyst Count
  • PHAT 4
  • HRTX 2
  • Target Price
  • PHAT $16.25
  • HRTX $5.50
  • AVG Volume (30 Days)
  • PHAT 2.2M
  • HRTX 2.1M
  • Earning Date
  • PHAT 05-01-2025
  • HRTX 05-06-2025
  • Dividend Yield
  • PHAT N/A
  • HRTX N/A
  • EPS Growth
  • PHAT N/A
  • HRTX N/A
  • EPS
  • PHAT N/A
  • HRTX N/A
  • Revenue
  • PHAT $81,859,000.00
  • HRTX $148,518,000.00
  • Revenue This Year
  • PHAT $195.45
  • HRTX $12.60
  • Revenue Next Year
  • PHAT $106.76
  • HRTX $13.66
  • P/E Ratio
  • PHAT N/A
  • HRTX N/A
  • Revenue Growth
  • PHAT 3055.70
  • HRTX 12.43
  • 52 Week Low
  • PHAT $2.21
  • HRTX $1.04
  • 52 Week High
  • PHAT $19.71
  • HRTX $3.93
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 54.83
  • HRTX 44.20
  • Support Level
  • PHAT $3.92
  • HRTX $1.82
  • Resistance Level
  • PHAT $4.35
  • HRTX $1.93
  • Average True Range (ATR)
  • PHAT 0.40
  • HRTX 0.11
  • MACD
  • PHAT 0.13
  • HRTX -0.01
  • Stochastic Oscillator
  • PHAT 85.63
  • HRTX 36.73

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Share on Social Networks: